Alnylam Pharmaceuticals, Inc.（ALNY）财务数据ALNYAlnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. (ALNY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is AMVUTTRA, accounting for 78.4% of total sales, equivalent to $1.01B. Other significant revenue streams include GIVLAARI and Other. Understanding this composition is critical for investors evaluating how ALNY navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Alnylam Pharmaceuticals, Inc. maintains a gross margin of 76.88%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 17.93%, while the net margin is 12.74%. These profitability ratios, combined with a Return on Equity (ROE) of 96.55%, provide a clear picture of how effectively ALNY converts its operational activities into shareholder value.

In the context of the broader market, ALNY competes directly with industry leaders such as ZTS and BIIB. With a market capitalization of $30.60B, it holds a significant position in the sector. When comparing efficiency, ALNY's gross margin of 76.88% stands against ZTS's 71.64% and BIIB's 65.46%. Such benchmarking helps identify whether Alnylam Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Alnylam's total revenue has shown strong growth, with Q2 2026 revenue reaching $1.29 billion, up from $1.17 billion in Q1 2026. However, net income remains a concern, with a net income of $164.49 million in Q2 2026 after a previous loss in Q1. The gross margin is healthy at 76.88%, but the company has faced challenges with a significant reduction in its full-year sales guidance for TTR products by $200 million.